To address mechanisms of demyelination and neuronal apoptosis in cortical lesions of inflammatory demyelinating disorders, different animal models are used. We here describe an ex vivo approach by using oligodendrocyte-specific CD8+ T-cells on brain slices, resulting in oligodendroglial and neuronal death. Potential applications and limitations of the model are discussed.
Death of oligodendrocytes accompanied by destruction of neurons and axons are typical histopathological findings in cortical and subcortical grey matter lesions in inflammatory demyelinating disorders like multiple sclerosis (MS). In these disorders, mainly CD8+ T-cells of putative specificity for myelin- and oligodendrocyte-related antigens are found, so that neuronal apoptosis in grey matter lesions may be a collateral effect of these cells. Different types of animal models are established to study the underlying mechanisms of the mentioned pathophysiological processes. However, although they mimic some aspects of MS, it is impossible to dissect the exact mechanism and time course of ‘‘collateral’’ neuronal cell death. To address this course, here we show a protocol to study the mechanisms and time response of neuronal damage following an oligodendrocyte-directed CD8+ T cell attack. To target only the myelin sheath and the oligodendrocytes, in vitro activated oligodendrocyte-specific CD8+ T-cells are transferred into acutely isolated brain slices. After a defined incubation period, myelin and neuronal damage can be analysed in different regions of interest. Potential applications and limitations of this model will be discussed.
Death of oligodendrocytes and destruction of the myelin sheath accompanied by loss of neurons and axons are typical pathological findings in grey matter lesions in individuals suffering from multiple sclerosis (MS)1,2. Cortical lesions can be divided so far in three different subtypes2: subpial, intracortical and leukocortical lesions. In comparison to white matter plaques, infiltrates are characterized by a predominance of CD8+ T-cells, suggesting their possible decisive role in grey matter inflammation3. Furthermore, oligoclonal expansions in blood, cerebrospinal fluid (CSF) and within inflammatory lesions can be found for CD8+ T-cells themselves4-6.
In line with this, it is assumed that CD8+ T-cells may be specific for different myelin proteins7,8. Indeed, CD8+ T-cells are found near oligodendrocytes and myelin sheaths9,10 that show MHC I expression11 and might therefore be responsible for the loss of the myelin sheath. This process is often seen together with extensive ‘‘collateral’’ neuronal and axonal damage within the central nervous system (CNS) grey matter1,2. In fact, direct and indirect death of oligodendrocytes and neurons is induced by CD8+ T-cells via two different mechanism: (i) cell membrane swelling and rupture due to the formation of cytotoxic granules following the release of perforins and granzymes and (ii) ligation to the Fas receptors or exposition of FasL on their surface8,12,13.
Different types of animal models are established to study the underlying mechanism of the mentioned processes. In this respect, primed CD8+ T-cells specific for autoantigens with induced expression in CNS glial cells, like oligodendrocytes or astrocytes, can be adoptively transferred to analyse ‘‘collateral’’ neuronal and axonal death in grey matter subsequently14,15. To perform such in vivo experiments is a big help to mimic some pathophysiological aspects of MS, however, this approach is not suited to resolve the underlying mechanism and kinetics of axonal damage and neuronal apoptosis.
To overcome these restrictions, an ex vivo approach was established to study the mechanisms and time course of neuronal cell death following a oligondendrocytes-directed CD8+ T-cell attack. Since only oligodendrocytes and therefore myelin sheath production should be targeted by immune cells, MHC class-I-restricted, ovalbumin (OVA)-reactive OT-I Tcells are used16. These cells are subsequently transferred into brain slices obtained from mice selectively expressing OVA in oligodendrocytes (ODC-OVA mice)17.
All experiments using mice should be performed in accordance with the guidelines of the respective institutional animal care and use committee.
1. General Comments for Mouse Experiments
2. Preparation and Activation of OVA-specific CD8+ T-cells (OT-I)
3. Preparation of Acute Brain Slices and Co-culture with OT-I T-cells
After incubation of brain slices with oligodendrocyte-directed CD8+ T-cells, oligodendrocytes as well as neurons undergo apoptosis (Figures 2A and 1C, respectively). Histological signs of apoptosis (e.g., Caspase-3, Tunel) can be earliest detected after 3 hr of incubation. Incubation period should not be longer than 8 hr in order to guarantee a good quality of the preparation and reproducible results. Apoptotic cells can be found all over the slice with preponderance in myelinated areas. Exemplary histological staining of the slice for structural integrity and apoptotic neurons is depicted in Figure 1A-C.
There are different time points during incubation which are of interest for assessing outcome parameters. A typical time course performed in our lab includes parameters analyses, namely, cell-cell interactions at time 0, then 3, 4 and 6 hr (the maximal interaction observed) after interaction started. Some typical assays beyond histological analyses which can often be applied are described very briefly:
T-cell recovery and analysis
After an incubation period up to 8 hr, T-cells can be recovered from slices and can be evaluated to analyse parameters relative to the intracellular effector molecules such as cytokine production or proliferation. In order to retrieve T-cells, slices were dissociated mechanically and pooled together for every experimental condition. Cells were isolated from the interface a 30% to 50% Percoll (Amersham, Freiburg, Germany) after density gradient centrifugation for 30 min at 2,500 rpm. In this way, it is possible to obtain mononuclear cells which were washed and stained immediately using flow cytometry techniques (FACS) using a different number and type of antibodies which vary depending on the study we want to address, in this protocol, for example CD8+ 18.
Neuronal collateral damage and functionality
Information about neuronal health and functionality can be assessed by performing electrophysiological recording e.g., to evaluate basic properties of the neurons such as action potentials (APs) generation, as shown in Figure 1D.
Figure 1. Morphological structure of slice as well as representative results. (A) Morphological structure of a slice 8 hr after incubation. Scale bar indicates 10 µm. (B) Neurons are synaptically interconnected as revealed by co-staining for MAPII (green) and synaptophysin (red) staining. Scale bar represents 10 µm. (C) Representative picture of apoptotic cells (Caspase-3, red) and neurons (NeuN, green) in the hippocampus after 6 hr incubation. Scale bar represents 10 µm. (D) Single cell patch-clamp recordings of neuronal action potential generation following depolarizing current steps in a murine cortical neuron. Please click here to view a larger version of this figure.
Figure 2. Multiple stainings performed to assess specifity of the protocol. (A) Co-staining of NogoA (red), a marker for mature oligodendrocytes (ODCs) and Caspase3 (apoptosis, green) shows that ODCs are attacked by CD8+ T cells. (B) Interaction result is negative when Caspase3 (red) is co-stained with GFAP, a marker for glial cells (green). Scale bar represent 10 µm. (C) Specificity of the protocol is supported by the co-staining of neuronal cells (DAPI, blue) with Caspase3 (red), starting from the left: WT animals, WT animals exposed to OTI-I T cells, ODC-Ova and ODC-Ova exposed to OTI-I T cells. Please click here to view a larger version of this figure.
Different animal models have been described over the last decades to address the pathological features of inflammatory demyelinating disorders like MS. In vivo mouse and rat models are widely used to mimic pathophysiological features of the disease, namely, analysis of the consequences of demyelination and remyelination processes and of intermingled episodes of inflammation and neurodegeneration. Nevertheless, only an ex vivo approach allows to dissect the exact underlying mechanisms.
Preparation of acute brain slices is also a widely distributed model and can be considered as reliable and replicable. In combination with the isolation and incubation of oligodendrocyte-specific immune cells, it can be used to address specific experimental questions, especially in terms of studying mechanism and kinetics of an immune cell attack and cell – cell interactions. Other ex vivo approaches are known and widely used22 but the novelty of our protocol in the specificity of the target that can be challenged by performing different “exclusion” co-stainings, namely verifying the Caspase3 immunoreactivity in WT exposed or not exposed to OT-I T cells (see Figure 2C).
Some critical points during the preparation should be taken into consideration, namely the experimental settings, to ensure that experiments are performed methodologically correct; for internal validity, isolation and stimulation of the used immune cells should be controlled on a regular basis via e.g., flow cytometry analyses (FACS). Moreover, checking vitality of brain slices is highly recommended. Experimental groups should be age- and sex-matched. Experiments should always be performed in compliance with animal welfare regulations.
Some limitations of the protocol need to be kept in mind. Most importantly, the presented model is an ex vivo approach and is not suited to fully mimic the complex immunological situation of autoimmune central nervous system disorders. It should also be considered that the model uses only CD8+ T-cell driven immunological response. CD4+ T-cells and B cells play a less prominent role. Alternative protocols using other oligodendrocyte-specific immune cell subtypes should be considered when addressing these cell types. The expected histological finding is oligodendroglial (see Figure 2A) and neuronal apoptosis (see Figure 1C). Alternatively, apoptosis of other cell types can be achieved using e.g., astroglial or neuronal antigen-specific immune cells and transgenic systems. In this specific protocol the immunoreactivity of Caspase3 in astroglial cells was negative due to the specificity of the system (Figure 2B).
The described protocol can be considered as a basic neuroimmunological experimental approach and may be modified for other applications. The experimental procedure can be easily applied to other protocols by varying brain slices (e.g., different transgenic mice strains) in combination with different antigen-specific immune cell subtypes (e.g., use myelin oligodendrocyte glycoprotein (MOG)- specific CD4+ T-cells and brain slices prepared from C57Bl/6 mice to address their effects on oligodendroglial and neuronal apoptosis). In vitro activation of immune cells can be varied for specific immunological questions (e.g., polarization into TH1 or TH17 cells).
Sometimes, enhanced or reduced apoptosis in brain slices might be an experimental challenge. Some recommendations for troubleshooting are:
At first, quality of brain slices is highly dependent of preparation time as well as pH value, osmolarity and oxidation status of used solution. It should be ensured that conditions are comparable between the independent experiments. Furthermore, activation of immune cells should be controlled on a regular basis. Optimal antigen concentration may vary. Consider a titration of the used antigen when establishing the experiments.
As described above, the mentioned protocol can be used as starting point for analyzing the effect of further immune cell subtypes (e.g., CD4+ T-cells, B-cells) on central nervous system integrity. These approaches are especially suited for separating their effects on oligodendroglial and neuronal cells as histological analysis can be assessed thoroughly.
The authors have nothing to disclose.
This work was supported by the Interdisciplinary Center for Clinical Research (IZKF) Münster (SEED 03/12, SB), Deutsche Forschungsgemeinschaft (SFB TR128, TP B6 to S.G.M. ME3283/2-1 to S.G.M.) and by Innovative Medizinische Forschung, Münster (I-BI111316, SB and SGM).
Name of Material/ Equipment | Company | Catalog Number | Comments/Description |
12-Well-plate | Corning | 3513 | |
2-Mercaptoethanol | Gibco | 31350-010 | |
2-Methylbutan | Roth | 3927.1 | |
70 µm strainer | Falcon | 352350 | |
CaCl2 | Merck | 1.02382.0500 | calcium chloride |
CD8+-isolation kit | Miltenyi Biotech | 130-090-859 | |
D(+)-glukose | Merck | 1.08337.1000 | |
DMEM | Gibco | 31966-021 | warm in 37 °C water bath before use |
EDTA | Sigma | E5134 | |
FCS | PAA Laboratories | A15-151 | fetal calve serum |
gentamicin | Gibco | 15750-060 | |
HEPES 1M | Gibco | 15630-050 | |
IL-2 | Peprotech | 212-12 | |
Isofluran | Abbott | 05260-05 | |
KCl | Merck | 1.04933.0500 | potassium chloride |
KHCO3 | Sigma | P9144 | potassium hydrogen carbonate |
L-Glutamine | Gibco | 35050-038 | |
MgSO4 | Merck | 1.05886.0500 | magnesium sulfate |
NaCl | Sigma | 31434 | sodium chloride |
NaH2PO4 * H2O | Merck | 1.06346.0500 | sodium hydrogen phosphate |
NaHCO3 | Merck | 1.06329.0500 | sodium hydrogen carbonate |
NaOH | Merck | 1.09137.1000 | sodium hydroxide |
NH4Cl | Sigma | 213330 | ammonium chloride |
Non Essential Amino Acid | Gibco | 11140-050 | |
OVA (257-264) | Genscript | RP10611 | ovalbumin |
PIPES | Sigma | P6757 | |
Sukrose | Merck | 1.07687.1000 | |
Tissue-Tek OCT | Sakura | 4583 |